Methods for treating non-cancerous disorders using hematopoietic cells

Abstract

The invention provides methods of treating non-cancerous disorders in a subject by providing the subject with compositions containing hematopoietic cells. In certain embodiments, the compositions include CD34 + cells and CD3 + cells. In certain embodiments, the compositions include CD34 + cells and facilitating cells. The methods are useful for treating blood cell disorders and other disorders that can be ameliorated by providing donor hematopoietic cells.

1 .- 28 . (canceled) 
     
     
         29 . A method of treating a non-cancerous disorder in a subject that has not and will not receive a solid organ transplant, the method comprising: providing a cellular product comprising CD34 +  cells and CD8 + /alpha beta TCR −  facilitating cells derived from a donor. 
     
     
         30 . The method of  claim 29 , wherein the facilitating cells are CD56 bright . 
     
     
         31 . The method of  claim 29 , wherein the facilitating cells are CD56 dim/neg . 
     
     
         32 . The method of  claim 29 , wherein the disorder is associated with aberrant activity of a hematopoietic cell. 
     
     
         33 . The method of  claim 32 , wherein the disorder is selected from the group consisting of agranulocytosis, anemia, aplasia, ataxia, a blood clotting disorder that is not due to deficiency of a blood clotting factor, bone marrow failure, cerebral adrenoleukodystrophy, chronic granulomatous disease, cytopenia, dyskeratosis congenita, Gaucher's disease, hemochromatosis, hemoglobin disorders, Hurler syndrome, leukodystrophy, metachromatic leukodystrophy, mitochondrial neurogastrointestinal encephalomyopathy, myelodysplastic syndrome, severe combined immunodeficiency, Shwachman-Diamond syndrome, sickle cell disease, sickle cell trait, thalassemia, and Wiskott-Aldrich syndrome. 
     
     
         34 . The method of  claim 29 , wherein the CD34 +  cells and the facilitating cells are HLA-matched to the subject. 
     
     
         35 . The method of  claim 29 , wherein the CD34 +  cells and the facilitating cells are HLA-mismatched to the subject. 
     
     
         36 . The method of  claim 29 , wherein the cellular product comprises CD3 +  cells derived from the donor. 
     
     
         37 . The method of  claim 36 , wherein the product comprises:
 at least 1×10 5  CD34 +  cells/kg recipient weight; and   at least 1×10 5  CD3 +  cells/kg recipient weight.   
     
     
         38 . The method of  claim 37 , wherein the product comprises:
 at least 1×10 6  CD34 +  cells/kg recipient weight; and   at least 1×10 6  CD3 +  cells/kg recipient weight.   
     
     
         39 . The method of  claim 38 , wherein the product comprises at least 4×10 6  CD34 +  cells/kg recipient weight. 
     
     
         40 . The method of  claim 38 , wherein the product comprises about 10 8  CD3 +  cells/kg recipient weight. 
     
     
         41 . The method of  claim 38 , wherein the product comprises:
 at least 4×10 6  CD34 +  cells/kg recipient weight; and   about 1×10 8  CD3 +  cells/kg recipient weight.